
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5526490/publications.pdf Version: 2024-02-01



FDDAL SAC

#	Article	lF	CITATIONS
1	Comparison of IVIG resistance predictive models in Kawasaki disease. Pediatric Research, 2022, 91, 621-626.	2.3	16
2	Spinal involvement in juvenile idiopathic arthritis: what do we miss without imaging?. Rheumatology International, 2022, 42, 519-527.	3.0	6
3	Assessment of systemic and ocular inflammation in juvenile idiopathic arthritis via choroidal vascularity index. Rheumatology International, 2022, 42, 1187-1196.	3.0	6
4	The difference of the inflammatory milieu in MIS-C and severe COVID-19. Pediatric Research, 2022, 92, 1805-1814.	2.3	24
5	Human OTULIN haploinsufficiency impairs cell-intrinsic immunity to staphylococcal α-toxin. Science, 2022, 376, eabm6380.	12.6	25
6	The challenges in diagnosing pediatric primary antiphospholipid syndrome. Lupus, 2022, 31, 1269-1275.	1.6	4
7	The Performances of the ACR 1997, SLICC 2012, and EULAR/ACR 2019 Classification Criteria in Pediatric Systemic Lupus Erythematosus. Journal of Rheumatology, 2021, 48, 907-914.	2.0	28
8	Performances of the "MS-score―And "HScore―in the diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis patients. Rheumatology International, 2021, 41, 87-93.	3.0	3
9	Defining colchicine resistance/intolerance in patients with familial Mediterranean fever: a modified-Delphi consensus approach. Rheumatology, 2021, 60, 3799-3808.	1.9	29
10	Inflammatory milieu of muscle biopsies in juvenile dermatomyositis. Rheumatology International, 2021, 41, 77-85.	3.0	8
11	Clinical features, muscle biopsy scores, myositis specific antibody profiles and outcome in juvenile dermatomyositis. Seminars in Arthritis and Rheumatism, 2021, 51, 95-100.	3.4	11
12	Plasma checkpoint protein levels and galectin-9 in juvenile systemic lupus erythematosus. Lupus, 2021, 30, 998-1004.	1.6	3
13	Genetic disorders with symptoms mimicking rheumatologic diseases: A single-center retrospective study. European Journal of Medical Genetics, 2021, 64, 104185.	1.3	2
14	Juvenile idiopathic arthritis: lymphocyte activation gene-3 is a central immune receptor in children with oligoarticular subtypes. Pediatric Research, 2021, 90, 744-751.	2.3	6
15	ECI Biocommentary: Erdal Sag. Pediatric Research, 2021, 90, 711-711.	2.3	0
16	Systematic review of childhood-onset polyarteritis nodosa and DADA2. Seminars in Arthritis and Rheumatism, 2021, 51, 559-564.	3.4	14
17	Real-world data on MTX tolerance with regimens used in children versus adults. Clinical Rheumatology, 2021, 40, 5095-5102.	2.2	2
18	Hematological involvement in pediatric systemic lupus erythematosus: A multi-center study. Lupus, 2021, 30, 1983-1990.	1.6	9

#	Article	IF	CITATIONS
19	The role of vascular inflammation markers in deficiency of adenosine deaminase 2. Seminars in Arthritis and Rheumatism, 2021, 51, 839-844.	3.4	7
20	Frequency of juvenile idiopathic arthritis and associated uveitis in pediatric rheumatology clinics in Turkey: A retrospective study, JUPITER. Pediatric Rheumatology, 2021, 19, 134.	2.1	15
21	Whole exome sequencing in unclassified autoinflammatory diseases: more monogenic diseases in the pipeline?. Rheumatology, 2021, 60, 607-616.	1.9	13
22	Deubiquitination of proteasome subunits by OTULIN regulates type I IFN production. Science Advances, 2021, 7, eabi6794.	10.3	8
23	ls Takayasu's arteritis more severe in children?. Clinical and Experimental Rheumatology, 2021, 39 Suppl 129, 32-38.	0.8	3
24	Validation of the EULAR/ACR 2017 idiopathic inflammatory myopathy classification criteria in juvenile dermatomyositis patients. Clinical and Experimental Rheumatology, 2021, 39, 688-694.	0.8	2
25	Is Takayasu's arteritis more severe in children?. Clinical and Experimental Rheumatology, 2021, 39, 32-38.	0.8	16
26	Validation of the EULAR/ACR 2017 idiopathic inflammatory myopathy classification criteria in juvenile dermatomyositis patients. Clinical and Experimental Rheumatology, 2021, 39, 688-694.	0.8	2
27	Performance of the new â€~Eurofever/PRINTO classification criteria' in FMF patients. Seminars in Arthritis and Rheumatism, 2020, 50, 172-175.	3.4	15
28	Predictive biomarkers of IgA vasculitis with nephritis by metabolomic analysis. Seminars in Arthritis and Rheumatism, 2020, 50, 1238-1244.	3.4	9
29	How the COVID-19 pandemic has influenced pediatric rheumatology practice: Results of a global, cross-sectional, online survey. Seminars in Arthritis and Rheumatism, 2020, 50, 1262-1268.	3.4	22
30	Kawasaki-like disease in children with COVID-19. Rheumatology International, 2020, 40, 2105-2115.	3.0	67
31	Colchicine and Leukopenia: Clinical Implications. Journal of Pediatrics, 2020, 224, 166-170.e1.	1.8	3
32	Clusters in Pediatric Rheumatic Diseases. Current Rheumatology Reports, 2020, 22, 28.	4.7	4
33	Response to letter to the editor. Seminars in Arthritis and Rheumatism, 2020, 50, 1553.	3.4	0
34	Ancient familial Mediterranean fever mutations in human pyrin and resistance to Yersinia pestis. Nature Immunology, 2020, 21, 857-867.	14.5	90
35	Epigenetics for Clinicians from the Perspective of Pediatric Rheumatic Diseases. Current Rheumatology Reports, 2020, 22, 46.	4.7	5
36	Childhood vasculitis. Rheumatology, 2020, 59, iii95-iii100.	1.9	18

#	Article	IF	CITATIONS
37	Anti-IL1 treatment in colchicine-resistant paediatric FMF patients: real life data from the HELIOS registry. Rheumatology, 2020, 59, 3324-3329.	1.9	22
38	Behçet Disease. Rare Diseases of the Immune System, 2020, , 161-175.	0.1	1
39	Expression of myxovirusâ€resistance protein A: a possible marker of muscle disease activity and autoantibody specificities in juvenile dermatomyositis. Neuropathology and Applied Neurobiology, 2019, 45, 410-420.	3.2	36
40	ls age associated with disease severity and compliance to treatment in children with familial Mediterranean fever?. Rheumatology International, 2019, 39, 83-87.	3.0	18
41	The Challenge of Treating Pulmonary Vasculitis in Behçet Disease: Two Pediatric Cases. Pediatrics, 2019, 144, .	2.1	9
42	The factors affecting the disease course in Kawasaki disease. Rheumatology International, 2019, 39, 1343-1349.	3.0	11
43	AB1041â€PREVALENCE OF JUVENILE IDIOPATHIC ARTHRITIS (JIA) SUBGROUPS AND JIA-ASSOCIATED UVEITIS AMONG JIA PATIENTS ADMITTED TO REFERRAL PEDIATRIC RHEUMATOLOGY CLINICS IN TURKEY: A RETROSPECTIVE STUDY, JUPITER. , 2019, , .		0
44	AB0960â€THE HELIOS (HACETTEPE UNIVERSITY ELECTRONIC RESEARCH FORMS) REGISTRY: USE OF BIOLOGIC DRUGS IN AUTOINFLAMMATORY DISEASES. , 2019, , .	2	0
45	OP0152â€OLIGOARTICULAR JUVENILE IDIOPATHIC ARTHRITIS DOES NOT SHOW SIGNS OF T-CELL EXHAUSTIC IN SPITE OF INCREASED EXPRESSION OF CO-INHIBITORY RECEPTORS. , 2019, , .	N,	0
46	AB0958â€PEDIATRIC BEHCET'S DISEASE WITH SINUS VENOUS THROMBOSIS: THREE CENTER EXPERIENCE TURKEY. , 2019, , .	FROM	0
47	SAT0493â€THE CHALLENGE OF TREATİNG PULMONARY VASCULITIS IN BEHÇET'S DISEASE: TWO PEDIA CASES. , 2019, , .	TRIC	0
48	THU0533â€IMPAIRED PLATELET FUNCTIONS IN PATIENTS TREATED WITH COLCHICINE. , 2019, , .		0
49	Evaluation of Choroidal Thickness, Choroidal Vascularity Index and Peripapillary Retinal Nerve Fiber Layer in Patients with Juvenile Systemic Lupus Erythematosus. Lupus, 2019, 28, 44-50.	1.6	38
50	Histological heterogeneity in a large clinical cohort of juvenile idiopathic inflammatory myopathy: analysis by myositis autoantibody and pathological features. Neuropathology and Applied Neurobiology, 2019, 45, 495-512.	3.2	36
51	Chronic recurrent multifocal osteomyelitis in children: a single center experience over five years. Turkish Journal of Pediatrics, 2019, 61, 386.	0.6	20
52	Systemic onset juvenile idiopathic arthritis: a single center experience. Turkish Journal of Pediatrics, 2019, 61, 852.	0.6	10
53	Vasculitis in Systemic Autoinflammatory Diseases. Frontiers in Pediatrics, 2018, 6, 377.	1.9	47
54	A new biopsychosocial and clinical questionnaire to assess juvenile idiopathic arthritis: JAB-Q. Rheumatology International, 2018, 38, 1557-1564.	3.0	4

#	Article	IF	CITATIONS
55	AB1452-HPRâ€Which one has a greater effect on function and the psychosocial status in jia?: disease type or the presence of pain. , 2018, , .		0
56	lgA vasculitis (Henoch–Schönlein purpura) in children. Expert Opinion on Orphan Drugs, 2017, 5, 405-410.	0.8	1
57	Biopsy pathology in a large cohort of juvenile dermatomyositis is heterogeneous and, for the most part, independent of autoantibody phenotype. Canadian Journal of Neurological Sciences, 2017, 44, S6-S6.	0.5	0
58	Autoinflammatory Diseases with Periodic Fevers. Current Rheumatology Reports, 2017, 19, 41.	4.7	66
59	Childhood systemic vasculitis. Best Practice and Research in Clinical Rheumatology, 2017, 31, 558-575.	3.3	18
60	Congenital Mirror Movements in Gorlin Syndrome: A Case Report With DTI and Functional MRI Features. Pediatrics, 2016, 137, e20151771.	2.1	5
61	Pediatric-onset adult type sarcoidosis: A case report. Archivos Argentinos De Pediatria, 2015, 113, .	0.2	0
62	How do tissue infiltrating B cells correlate with other inflammatory features in muscle tissue from patients with JDM and their clinical parameters?. Neuromuscular Disorders, 2015, 25, S247-S248.	0.6	0
63	Inflammatory milieu of muscle biopsies and clinical features in juvenile dermatomyositis. Neuromuscular Disorders, 2015, 25, S248.	0.6	0
64	Neuroblastoma in a Patient With Spinal Muscular Atrophy Type I. Journal of Child Neurology, 2015, 30, 1075-1078.	1.4	3
65	Hyperthyroidism After Allogeneic Hematopoietic Stem Cell Transplantation: A Report of Four Cases. JCRPE Journal of Clinical Research in Pediatric Endocrinology, 2015, 7, 349-354.	0.9	14
66	What we miss if standard panel is used for skin prick testing?. Asian Pacific Journal of Allergy and Immunology, 2015, 33, 211-21.	0.4	4
67	Sub-phenotyping of juvenile dermatomyositis: can it assist clinical decisions?. Pediatric Rheumatology, 2014, 12, .	2.1	1
68	How do tissue infiltrating B cells and plasma cells correlate with other inflammatory features in muscle tissue from patients with JDM?. Pediatric Rheumatology, 2014, 12, .	2.1	0
69	Tubuloreticular inclusions in juvenile dermatomyositis: a diagnostically useful marker?. Pediatric Rheumatology, 2014, 12, .	2.1	0
70	A Rare Cause of Elevated Chitotriosidase Activity: Glycogen Storage Disease Type IV. JIMD Reports, 2014, 17, 63-66.	1.5	4
71	G.P.233. Neuromuscular Disorders, 2014, 24, 886-887.	0.6	0
72	Successful treatment of severe myasthenia gravis developed after allogeneic hematopoietic stem cell transplantation with plasma exchange and rituximab. Pediatric Blood and Cancer, 2014, 61, 928-930.	1.5	14

#	Article	IF	CITATIONS
73	Decrease in the rate of secondary amyloidosis in Turkish children with FMF: are we doing better?. European Journal of Pediatrics, 2010, 169, 971-974.	2.7	27